Free Trial

Avidity Biosciences (RNA) Stock Price, News & Analysis

-0.74 (-2.50%)
(As of 11:16 AM ET)
Today's Range
50-Day Range
52-Week Range
233,683 shs
Average Volume
1.12 million shs
Market Capitalization
$2.76 billion
P/E Ratio
Dividend Yield
Price Target

Avidity Biosciences MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
39.5% Upside
$41.33 Price Target
Short Interest
11.91% of Shares Sold Short
Dividend Strength
News Sentiment
0.47mentions of Avidity Biosciences in the last 14 days
Based on 16 Articles This Week
Insider Trading
Selling Shares
$7.66 M Sold Last Quarter
Proj. Earnings Growth
From ($3.10) to ($3.28) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.95 out of 5 stars

Medical Sector

808th out of 920 stocks

Pharmaceutical Preparations Industry

381st out of 430 stocks

RNA stock logo

About Avidity Biosciences Stock (NASDAQ:RNA)

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

RNA Stock Price History

RNA Stock News Headlines

Dip Then Rip? 3 Nasdaq Stocks to Buy Before the Rebound
Avidity Biosciences Inc (RNA)
Avidity Biosciences files automatic mixed shelf
See More Headlines
Receive RNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
6 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$9.56 million
Book Value
$8.69 per share


Free Float
Market Cap
$2.83 billion
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Dr. Troy Edward Wilson J.D. (Age 55)
    Ph.D., Co-Founder & Independent Chairman
    Comp: $70k
  • Ms. Sarah Boyce (Age 52)
    President, CEO & Director
    Comp: $998.88k
  • Mr. Michael F. MacLean (Age 58)
    Chief Financial & Chief Business Officer
    Comp: $674.74k
  • Dr. W. Michael F. Flanagan Ph.D. (Age 61)
    Chief Scientific & Technical Officer
    Comp: $675.22k
  • Ms. Teresa McCarthy (Age 60)
    Chief Human Resources Officer
    Comp: $628.79k
  • Dr. Arthur A. Levin Ph.D. (Age 70)
    Distinguished Scientist, Strategic Leader & Director
    Comp: $304.69k
  • Mr. Eric B. Mosbrooker (Age 57)
    Chief Strategy Officer
    Comp: $45k
  • Prof. Mark E. Davis Ph.D.
    Scientific Founder, Member of Scientific Advisory Board and Member of Board of Managers
  • Dr. Frank P. McCormick Ph.D. (Age 74)
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Geoffrey M. Grande C.F.A.
    VP of Investor Relation & Corporate Communication

RNA Stock Analysis - Frequently Asked Questions

Should I buy or sell Avidity Biosciences stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avidity Biosciences in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RNA shares.
View RNA analyst ratings
or view top-rated stocks.

What is Avidity Biosciences' stock price target for 2024?

6 brokers have issued 1 year price objectives for Avidity Biosciences' stock. Their RNA share price targets range from $30.00 to $60.00. On average, they predict the company's stock price to reach $41.33 in the next twelve months. This suggests a possible upside of 39.5% from the stock's current price.
View analysts price targets for RNA
or view top-rated stocks among Wall Street analysts.

How have RNA shares performed in 2024?

Avidity Biosciences' stock was trading at $9.05 at the start of the year. Since then, RNA shares have increased by 227.3% and is now trading at $29.62.
View the best growth stocks for 2024 here

When is Avidity Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our RNA earnings forecast

How were Avidity Biosciences' earnings last quarter?

Avidity Biosciences, Inc. (NASDAQ:RNA) posted its quarterly earnings data on Wednesday, May, 15th. The biotechnology company reported ($0.79) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.02. The biotechnology company earned $3.54 million during the quarter, compared to the consensus estimate of $7.09 million. Avidity Biosciences had a negative trailing twelve-month return on equity of 37.98% and a negative net margin of 2,103.78%.

What other stocks do shareholders of Avidity Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avidity Biosciences investors own include GTX (GTXI), Inovio Pharmaceuticals (INO), Novavax (NVAX), Sarepta Therapeutics (SRPT), Avid Bioservices (CDMO), Dynavax Technologies (DVAX), iBio (IBIO), Intel (INTC), Ariad Pharmaceuticals (ARIA) and Corcept Therapeutics (CORT).

When did Avidity Biosciences IPO?

Avidity Biosciences (RNA) raised $150 million in an IPO on Friday, June 12th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO.

Who are Avidity Biosciences' major shareholders?

Avidity Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (7.77%), Avoro Capital Advisors LLC (6.09%), Vanguard Group Inc. (4.02%), RA Capital Management L.P. (3.43%), Janus Henderson Group PLC (1.30%) and Alethea Capital Management LLC (0.80%). Insiders that own company stock include Arthur A Levin, Michael F Maclean, Rtw Investments, Lp, Sarah Boyce and W Michael Flanagan.
View institutional ownership trends

How do I buy shares of Avidity Biosciences?

Shares of RNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RNA) was last updated on 5/23/2024 by Staff

From Our Partners